
Melanoma vaccine in phase 3: towards approval in 2025
Moderna and Merck's vaccine reduces melanoma death rate by 62%, moving closer to FDA approval in 2025
Moderna and Merck's vaccine reduces melanoma death rate by 62%, moving closer to FDA approval in 2025
Experts say mRNA technology has accelerated the development of remedies against cancer, cardiovascular and autoimmune diseases.
The drug company could "cash in on" the mRNA cancer vaccine it is helping to deliver.
In a video call with investors, Moderna warns of new waves coming for Covid-19
News about the world of tomorrow.
We give news about the future of technology, science and society: if there is one thing that is about to arrive, it has already arrived here.
Category
Language editions
fffdddddd
To provide the best experiences, we and our partners use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and to show (non-)personalized ads. Not consenting or withdrawing consent may adversely affect some features and functions.
Click below to agree to the above or to make detailed choices. Your choices will apply only to this site. You can change your settings at any time, including withdrawing your consent, by using the Cookie Policy buttons or by clicking the manage consent button at the bottom of the screen.